ATE499349T1 - Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon - Google Patents

Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon

Info

Publication number: ATE499349T1
Authority: AT; Austria
Prior art keywords: sup; glucocorticoid receptor; nfkb; modulators; receptor activity
Prior art date: 2005-01-13

Application number

AT06718407T

Other languages

English (en)

Inventor

James E Sheppeck

T G Murali Dhar

Arthur M P Doweyko

Lidia M Doweyko

John L Gilmore

David S Weinstein

Hai-Yun Xiao

Bingwei Vera Yang

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-13

Filing date

2006-01-13

Publication date

2011-03-15

2006-01-13 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE499349T1 publication Critical patent/ATE499349T1/de

Links

102000003676 Glucocorticoid Receptors Human genes 0.000 title abstract 2
108090000079 Glucocorticoid Receptors Proteins 0.000 title abstract 2
230000000694 effects Effects 0.000 title abstract 2
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
208000008589 Obesity Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 2
235000020824 obesity Nutrition 0.000 abstract 2
102000003945 NF-kappa B Human genes 0.000 abstract 1
108010057466 NF-kappa B Proteins 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000003637 steroidlike Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Transplantation (AREA)
Biotechnology (AREA)

AT06718407T 2005-01-13 2006-01-13 Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon ATE499349T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64350905P	2005-01-13	2005-01-13
US11/330,553 US7361654B2 (en)	2005-01-13	2006-01-12	Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
PCT/US2006/001328 WO2006076632A1 (en)	2005-01-13	2006-01-13	SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFκB ACTIVITY AND USE THEREOF

Publications (1)

Publication Number	Publication Date
ATE499349T1 true ATE499349T1 (de)	2011-03-15

Family

ID=36654083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06718407T ATE499349T1 (de)	2005-01-13	2006-01-13	Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon

Country Status (6)

Country	Link
US (1)	US7361654B2 (de)
EP (1)	EP1896434B1 (de)
JP (1)	JP2008526993A (de)
AT (1)	ATE499349T1 (de)
DE (1)	DE602006020273D1 (de)
WO (1)	WO2006076632A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7625921B2 (en) *	2004-01-16	2009-12-01	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) *	2004-01-16	2008-02-05	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7569689B2 (en) *	2004-01-16	2009-08-04	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) *	2004-01-16	2007-09-25	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7253283B2 (en) *	2004-01-16	2007-08-07	Bristol-Myers Squibb Company	Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) *	2004-01-16	2009-10-20	Bristol-Myers Squibb Company	Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1988095B1 (de) *	2007-04-27	2016-01-27	Euticals GmbH	Verfarhen zur Herstellung von Aminoaryl- bzw. heteroarylboronsaeuren und ihren Derivaten
TWI654180B (zh)	2012-06-29	2019-03-21	美商艾佛艾姆希公司	殺真菌之雜環羧醯胺
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
KR101935636B1 (ko) *	2016-11-04	2019-01-07	에스티팜 주식회사	(s)-n1-(2-아미노에틸)-3-(4-알콕시페닐)프로판-1,2-디아민 3염산염의 제조방법
WO2018195155A1 (en) *	2017-04-18	2018-10-25	Celgene Quanticel Research, Inc.	Therapeutic compounds
CN107162999B (zh) *	2017-06-30	2022-06-10	淮海工学院	2-苯基-4-对羟基苯基噻唑的合成方法
CN109481683B (zh) *	2018-12-19	2021-07-02	四川大学华西医院	α受体阻滞剂在制备治疗急性胰腺炎的药物中的应用
US11884652B2 (en)	2020-06-29	2024-01-30	Boehringer Ingelheim International Gmbh	Tetrazole derivatives as TRPA1 inhibitors
CN117083269A (zh)	2021-04-14	2023-11-17	勃林格殷格翰国际有限公司	作为trpa1抑制剂的尿嘧啶衍生物
CN114735795B (zh) *	2022-04-29	2023-04-25	扬州工业职业技术学院	一种海藻酸钠-硅藻土复合磁性絮凝剂及其制备方法
WO2024002270A1 (en) *	2022-06-29	2024-01-04	Shanghai Yao Yuan Biotechnology Co., Ltd.	Alpha protein kinase 1 inhibitors for use in treating kidney diseases and kidney-related diseases
CN115974723B (zh) *	2022-12-27	2024-10-25	中国药科大学	甲酰胺乙撑蒽类化合物、包含其的药物组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3317387A (en)	1964-05-25	1967-05-02	Du Pont	Method of reducing the severity of influenza virus infections
US3422104A (en)	1964-10-20	1969-01-14	Geigy Chem Corp	9,10-dihydro-11-amino-alkylene-9,10-ethanoanthracenes
US3517073A (en)	1967-06-13	1970-06-23	Eastman Kodak Co	Synthesis of a hydroxy group-containing polycyclic aromatic fused ring compound
CS198678B1 (cs)	1978-03-17	1980-06-30	Jaroslav Horyna	Způsob přípravy 9,10-dihydro-9,10-ethanoantracenových derivátů
US4786646A (en)	1987-07-10	1988-11-22	Hoffmann-La Roche Inc.	Cyclopropylpropenamides
ES2078922T3 (es)	1989-06-29	1996-01-01	Searle & Co	Derivados de cicloheteroetanoantraceno dihetero nitrogenados utiles como agentes antipsicoticos.
US5055468A (en)	1989-10-30	1991-10-08	G. D. Searle & Co.	Use of bridged tricyclic amine derivatives as anti-ischemic agents
US5202486A (en)	1990-07-31	1993-04-13	E. R. Squibb & Sons, Inc.	Tetrahydroethanonaphthaleneamine derivatives
US5332820A (en)	1991-05-20	1994-07-26	E. I. Du Pont De Nemours And Company	Dibenzobicyclo(2.2.2) octane angiotensin II antagonists
GB9316722D0 (en)	1993-08-12	1993-09-29	Black James Foundation	Bicyclo (2.2.2)octane derivatives
US5514683A (en)	1992-02-20	1996-05-07	James Black Foundation Limited	Bicyclo 2,2,2!octane derivatives
NZ249202A (en)	1992-02-20	1996-06-25	Black James Foundation	Bicyclo[2.2.2.]octane derivatives, preparation and pharmaceutical compositions thereof
MX9303670A (es)	1992-06-19	1994-05-31	Black James Foundation	Derivados de biciclooctano y bicicloheptano, meto do para su preparacion y composiciones farmaceuticas que los contienen.
US5455248A (en)	1993-09-14	1995-10-03	Sterling Winthrop Inc.	Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts, and compositions and method of use thereof
US5569655A (en)	1993-09-14	1996-10-29	Sterling Winthrop Inc.	Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
US5461054A (en)	1993-12-09	1995-10-24	Bayer Aktiengesellschaft	Anthracene-spiro-pyrrolindines
US5411960A (en)	1993-12-09	1995-05-02	Bayer Aktiengesellschaft	Substituted pyrroloanthracenes and -diones
US5409932A (en)	1993-12-09	1995-04-25	Bayer Ag	Piperazine-substituted pyrroloanthracenes
EP0727410A1 (de)	1995-02-08	1996-08-21	Ciba-Geigy Ag	Bisphenolesterderivate
US6262059B1 (en)	1995-06-07	2001-07-17	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with quinazoline derivatives
DE19742014A1 (de)	1997-09-24	1999-03-25	Roche Diagnostics Gmbh	Neue Tetracyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6214915B1 (en)	1998-12-10	2001-04-10	General Electric Company	Stabilized thermoplastic compositions
FR2796641B1 (fr)	1999-07-22	2001-09-21	Aventis Pharma Sa	Nouveau procede de preparation de composes benzoperhydroisoindole
AU2002230781A1 (en)	2000-12-22	2002-07-08	Celltech R And D, Inc.	Pharmaceutical uses and synthesis of benzobicyclooctanes
TWI263640B (en)	2001-12-19	2006-10-11	Bristol Myers Squibb Co	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE60309909T2 (de)	2002-06-19	2007-06-21	Karo Bio Ab	Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
SI1521733T1 (sl)	2002-07-08	2014-10-30	Pfizer Products Inc.	Modulatorji glukokortikoidnega receptorja
JP2006508042A (ja)	2002-07-18	2006-03-09	ブリストル−マイヤーズ　スクイブ　カンパニー	グルココルチコイド受容体の修飾物質および方法
US7326728B2 (en)	2004-01-16	2008-02-05	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7569689B2 (en)	2004-01-16	2009-08-04	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7625921B2 (en)	2004-01-16	2009-12-01	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en)	2004-01-16	2009-10-20	Bristol-Myers Squibb Company	Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof

2006
- 2006-01-12 US US11/330,553 patent/US7361654B2/en not_active Expired - Lifetime
- 2006-01-13 DE DE602006020273T patent/DE602006020273D1/de not_active Expired - Lifetime
- 2006-01-13 WO PCT/US2006/001328 patent/WO2006076632A1/en not_active Ceased
- 2006-01-13 AT AT06718407T patent/ATE499349T1/de not_active IP Right Cessation
- 2006-01-13 JP JP2007551423A patent/JP2008526993A/ja active Pending
- 2006-01-13 EP EP06718407A patent/EP1896434B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US7361654B2 (en)	2008-04-22
JP2008526993A (ja)	2008-07-24
US20060154973A1 (en)	2006-07-13
EP1896434A1 (de)	2008-03-12
DE602006020273D1 (de)	2011-04-07
EP1896434B1 (de)	2011-02-23
WO2006076632A1 (en)	2006-07-20

Legal Events

Date	Code	Title	Description
2011-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE499349T1 (de)	2011-03-15	Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon
EA200800172A1 (ru)	2008-08-29	2,4-диаминопиримидины как ингибиторы aurora
MY151348A (en)	2014-05-15	Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
ES2282685T3 (es)	2007-10-16	Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
EA200700489A1 (ru)	2007-10-26	Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA200700035A1 (ru)	2007-06-29	Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
NZ612000A (en)	2015-05-29	Bicyclo[3.2.1]octyl amide derivatives and uses of same
MA31889B1 (fr)	2010-12-01	N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci
GEP20156348B (en)	2015-08-25	Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MA32811B1 (fr)	2011-11-01	Nouveaux composés
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
PT2139334E (pt)	2013-10-02	Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
DK2212282T3 (da)	2012-01-23	Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
PT1716152E (pt)	2008-10-02	Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais
WO2007112014A3 (en)	2007-12-21	New therapeutic combinations for the treatment of depression
EA200602243A1 (ru)	2007-04-27	3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE494926T1 (de)	2011-01-15	Neuartige p2x7r-antagonisten und ihre verwendung
UA92496C2 (ru)	2010-11-10	Производные оксадиазола и их применение как положительных аллостерических модуляторов метаботропных глутаматных рецепторов
ATE414090T1 (de)	2008-11-15	Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
DK1725536T3 (da)	2009-02-16	Imidazolin-derivater med CB1-antagonistisk aktivitet
ATE546439T1 (de)	2012-03-15	Heterocyclische modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb- aktivität und deren verwendung
DE602006020246D1 (de)	2011-04-07	Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb-aktivität und deren verwendung
ATE412636T1 (de)	2008-11-15	Piperazinylpyridinderivate als mittel gegen adipositas
ATE407119T1 (de)	2008-09-15	Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
ATE505193T1 (de)	2011-04-15	Arzneimittelkombinationen zur behandlung von atemwegserkrankungen